ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Sulfasalazine mitigates cisplatin-induced nephrotoxicity via NF-κB downregulation and upstream modulation of p-AMPK, SIRT1, miRNA-132-3p, and miRNA-375.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study tested for the first time the safety of sulfasalazine at dose of 100 mg/kg on renal function, in addition to study its possible renal effects on cisplatin-induced nephrotoxicity in rat model. Furthermore, it aimed to investigate the modulatory effect of sulfasalazine on NF-κB. Forty-eight male Sprague-Dawley rats were divided into four groups: negative control (given a daily oral dose of normal saline), cisplatin (given a single dose of Cisplatin, 6 mg/kg, i.p.; nephrotoxicity model), sulfasalazine (given a daily dose of SFZ, 100 mg/kg, orally via gavage; control model), and Cis + SFZ (given 100 mg/kg sulfasalazine, orally, 5 days before and 14 days after the cisplatin dose). Nephrotoxicity was evaluated 96 h and 14 days following cisplatin administration. Cisplatin nephrotoxicity was evidenced by significant rises in renal indices of functional, inflammatory, fibrotic, apoptotic and histological profiles. It also up-regulated miR-375 and miR-132-3p expression. Decreased p-AMPK, SIRT-1, HNF-1B and total antioxidant levels in kidney homogenates were also observed at 96 h following cisplatin injection. Sulfasalazine alone didn't show any change in renal parameters compared to the saline-treated group but counteracted cisplatin-induced nephrotoxic changes. The obtained results revealed that sulfasalazine at the dose of 100 mg/kg offered a renoprotective effects against cisplatin-induced nephrotoxicity which could be attributed to its inhibition of NF-κB-p65 via downstream attenuation of inflammatory, apoptotic and fibrotic pathway. This inhibitory effect of sulfasalazine on NF-κB-p65 could be at least in part attributed to its upstream modulation of p-AMPK, SIRT1, miRNA-132-3p and miR-375.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.